PANC-1 Gemcitabine-Resistant PDAC Model Service

The PANC-1 Gemcitabine-Resistant PDAC Model Service delivers a fully characterized in vitro and in vivo system for studying the gemcitabine resistance that limits therapy in pancreatic ductal adenocarcinoma (PDAC). Alfa Cytology provides end-to-end support for this model—chronic stepwise gemcitabine selection in adherent PANC-1 culture, resistance-index benchmarking against matched parental controls, transporter- and metabolism-oriented mechanism profiling, and optional resistant xenograft cohorts with gemcitabine treatment arms in immunodeficient mice—so that clients can pursue chemoresistance and sensitization programs on a validated, well-documented foundation.

Overview of PANC-1 Gemcitabine-Resistant PDAC Model

The PANC-1 gemcitabine-resistant PDAC model is developed from PANC-1, a human pancreatic ductal adenocarcinoma cell line that is intrinsically among the more gemcitabine-refractory pancreatic lines, with parental IC₅₀ values reported in the low-to-mid micromolar range (roughly 2–40 µM depending on assay conditions). Through prolonged, stepwise exposure to gemcitabine, surviving subclones acquire dramatically reduced drug sensitivity, producing resistant sublines documented in the literature as PANC-1/GR, PANC-1RG, PANC-1RG7, or PANC-1-GemR. Reported resistance indices reach approximately 26- to 43-fold—for example, one well-characterized PANC-1/GR line showed an IC₅₀ increase from 1.96 µM to 83.50 µM—together with cross-resistance to 5-fluorouracil, methotrexate, and cisplatin in several isolates, closely reflecting the chemotherapy-refractory behavior of PDAC in the clinic.

Fig 1. Drug-resistance protein profiling of the PANC-1 gemcitabine-resistant model — P-gp/MRP1/LRP-MVP/Topo2/GSTP1 Westerns of PANC-1 and PANC-1/Gem under Gem±Ori treatment, with MRP1 and GSTpi densitometric quantification showing downregulation by oridonin. (Wang, Bili, et al., 2019)

Mechanistically, gemcitabine resistance in PANC-1 is governed by the nucleoside-transport-and-metabolism axis that controls intracellular drug availability. Gemcitabine is a hydrophilic nucleoside analog that cannot diffuse across the membrane and depends on the human equilibrative nucleoside transporter 1 (hENT1/SLC29A1) for cellular entry; inside the cell it requires phosphorylation by deoxycytidine kinase (dCK) to its active diphosphate and triphosphate metabolites, which inhibit ribonucleotide reductase (RRM1/RRM2) and incorporate into DNA to trigger S-phase arrest and apoptosis. Resistant PANC-1 cells characteristically down-regulate hENT1 and dCK while overexpressing RRM1/RRM2, MRP1, and the catabolic enzymes cytidine deaminase and dCMP deaminase. Layered on this pharmacologic resistance are elevated ERK/MAPK signaling (a hallmark of the PANC-1 background), EMT driven through TWIST1/Slug with NICD/Gli1 pathway activation, anti-apoptotic programs such as GATA1–Bcl-XL, ferroptosis suppression by lncRNAs like MACC1-AS1, autophagy induction, and enrichment of CD24₊/CD44₊/ESA₊ or CD133₊ cancer stem cell–like populations with metabolic reprogramming toward oxidative phosphorylation. Because these mechanisms operate simultaneously, the paired parental/resistant PANC-1 system—extendable into immunodeficient-mouse xenografts with gemcitabine treatment arms (commonly 50 mg/kg weekly)—serves as a rigorous preclinical platform for validating nucleoside transporter targeting, RRM1 inhibition, ferroptosis inducers, and rational combination regimens.

Principles of PANC-1 Gemcitabine-Resistant PDAC Model Construction

Model construction applies chronic, intermittent selection with a nucleoside analog in adherent culture. Because PANC-1 is already moderately gemcitabine-refractory, exposure begins near the measured parental IC₅₀ and is raised stepwise over several months: each cycle applies drug pressure for days, surviving cells regrow to confluence during drug-free recovery phases, and the concentration is then incremented. Cells that survive each escalation—typically those with reduced drug uptake, enhanced drug catabolism, reinforced nucleotide synthesis, or apoptosis evasion—expand until they dominate the culture. The stable phenotype is verified to persist after drug withdrawal before the subline is considered established.

Our Services

Built on months of disciplined selection practice and mechanism-driven characterization, Alfa Cytology provides the PANC-1 gemcitabine-resistant PDAC model as a turnkey preclinical asset: clients receive authenticated resistant cell banks with quantified resistance indices, matched parental controls, transporter/metabolism/signaling profiling, and—where a whole-tumor readout is required—resistant xenograft cohorts with gemcitabine treatment arms, all documented in traceable study reports ready for chemosensitizer screening and combination-program design.

Workflow of PANC-1 Gemcitabine-Resistant PDAC Model Construction

Construction proceeds as a monitored, multi-month escalation program in which each concentration step is gated by demonstrated regrowth, and each milestone is confirmed with quantitative sensitivity testing against parental controls. Baseline characterization of the parental line precedes selection; phenotypic confirmation precedes molecular profiling; and an optional xenograft stage extends validated resistance into immunodeficient mice. The typical sequence includes the following steps:

1. Parental line qualification and baseline profiling: PANC-1 cells are revived, authenticated, and mycoplasma-tested; baseline gemcitabine IC₅₀, doubling time, and basal hENT1/dCK/RRM1 expression are documented as reference values.
2. Initiation of gemcitabine exposure: Early-passage adherent cells are exposed to a gemcitabine concentration near the parental IC₅₀ (tens of nM) with medium refreshed every 2–3 days while morphology and viability are recorded.
3. Stepwise dose escalation: Once cultures demonstrate stable regrowth, the concentration is raised incrementally (e.g., 30 → 60 → 100 → 150 → 200 nM, then into the low micromolar range) over 6–12 months until cells proliferate robustly at a maintenance level of 0.1–1 µM or higher.
4. Stabilization and drug-free rest: The resistant pool is passaged continuously under selection pressure, then cultured without gemcitabine for one to two weeks to verify that the reduced response is heritable and not residual-drug carryover.
5. In vitro resistance confirmation. Gemcitabine dose–response curves are generated by MTT/CCK-8 or SRB assay for parental and resistant cells, the resistance index is calculated from IC₅₀ values, and clonogenic and sphere-formation assays confirm long-term fitness.
6. Molecular and phenotypic profiling: Transport/metabolism readouts (hENT1, dCK, RRM1/RRM2, cytidine deaminase, MRP1), signaling analysis (pERK, NICD/Gli1, GATA1–Bcl-XL), ferroptosis and autophagy markers, and EMT/stemness markers (E-cadherin, vimentin, CD24/CD44/ESA or CD133) map the resistance landscape.
7. Resistant xenograft establishment (optional: in vivo stage). Validated resistant cells are inoculated subcutaneously into immunodeficient mice (typically 5 × 10⁶ cells per site, often with Matrigel), and gemcitabine treatment arms (commonly 50 mg/kg i.p. weekly) benchmark resistant tumors against parental xenografts.
8. Quality control and release: A release package covering authentication, mycoplasma status, passage history, resistance-index reports, molecular profiling, and xenograft characterization is finalized before the model is delivered for study use.

Fig 2. PANC-1 Gemcitabine-Resistant PDAC Model Construction Workflow.

Case Study-PANC-1 Gemcitabine-Resistant PDAC Model Development

In a representative preclinical engagement, the Alfa Cytology team generated and characterized a gemcitabine-resistant PANC-1 subline for a client investigating rational combination and sensitization strategies against refractory PDAC. Sustained stepwise selection produced a stable resistant population with a clearly elevated resistance index relative to parental cells, and profiling highlighted nucleoside-transport down-regulation together with RRM1 up-regulation and an EMT/stem-like phenotypic shift. The validated subline was applied to combination-treatment screening, and complementary xenograft studies with gemcitabine treatment arms contextualized cellular findings at the whole-tumor level. Engagement-specific datasets and study reports from this and similar programs are available upon request under confidentiality.

Why Choose Alfa Cytology?

Alfa Cytology couples meticulous nM-to-µM escalation practice with mechanism-driven characterization, ensuring that every PANC-1 gemcitabine-resistant model is stable, traceable, and immediately useful for chemoresistance research. Distinct reasons to work with us include:

• Refined nM-to-µM escalation methodology producing stable, heritable gemcitabine resistance.
• Quantitative resistance-index benchmarking against matched parental controls with orthogonal assay confirmation.
• Comprehensive mechanism profiling spanning nucleoside transport, drug metabolism, signaling, ferroptosis, and stemness.
• Optional in vivo stage featuring resistant xenografts with standard gemcitabine treatment arms.
• Full traceability via authentication, mycoplasma screening, passage logs, and milestone-based reporting.
• Confidential, adaptive project management aligned to chemosensitizer and combination-program timelines.

Contact Us

If your PDAC research program requires a validated gemcitabine-resistant model, contact us today to discuss how the PANC-1 gemcitabine-resistant PDAC model can strengthen your preclinical studies. Reach out to the Alfa Cytology team for a customized study plan, timeline, and quotation tailored to your research goals.

For research use only. Not intended for any clinical use.